0

Close
 
Upcoming Allied Market Research
2023
Hiv Diagnosis Market

HIV Diagnosis Market

by Technology (Antibody Tests, Viral Load Tests, CD4 Tests, Tests for Early Infant Diagnosis, Tests for Viral Identification) and by Application (Diagnostic laboratories, Hospitals, Blood Banks, Home care settings, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Diagnostics and Biotech
Report Code: A02480
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Hiv Diagnosis Market

Request Now !

The diagnosis of HIV detects the presence of the human immunodeficiency virus (HIV), which causes the acquired immunodeficiency syndrome (AIDS). This is done by carrying out certain tests in serum, saliva, or urine samples. These tests may detect antibodies, antigens, or RNA. The increasing awareness about HIV, confidentiality of the test, and appropriate counseling increases the demand for this process.

The major factors that contribute to the growth of the global HIV diagnosis market includes the increasing prevalence of HIV/AIDS worldwide, increasing number of blood transfusions & blood donations that cause infections, which lead to HIV, benefits offered by point-of-care instruments & kits, technological advancements, and increasing government initiatives. However, high costs of Nucleic Acid Testing (NAT) and lack of mandates for NAT in developing countries are the major factors that restrain the growth of this market. Recent advancements of simple rapid assays with visual testing and easy handling home sample collection techniques that can be used by health care workers and consumers at home has carved ways to expand this market.

This market has been classified by technology into antibody tests, viral load tests, CD4 tests, and early infant diagnosis tests. On the basis of application it has been segmented into diagnostic laboratories, home care settings, hospitals, and blood banks. Geographically, the market has been divided into North America, Europe, Asia-Pacific and LAMEA.

The key players in the HIV diagnosis market profiled in this report are Siemens-AG, Roche Diagnostics AG, Abbott Laboratories, Danaher Corporation, Thermo-Fisher Scientific Inc., Merck & Co., Becton-Dickinson and Company, Hologic, Inc., Alere Inc., and Bio-Rad Laboratories (U.S.).

KeyBenefits

  • Market analysis for the global HIV diagnosis market, with region-specific assessments and competition analysis on a global and regional scale.
  • It provides extensive information about the current and upcoming trends in the global HIV diagnosis market which helps find opportunities in this field.
  • Market definition along with the identification of key drivers and restraints.
  • Identification of factors instrumental in changing the market scenario, raising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their market shares.
  • A wide-ranging knowledge & insights about the major players in this industry, along with the key strategies adopted by them to sustain and grow in the studied market.
  • Insights on major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.

 HIV Diagnosis Market Report Highlights

Aspects Details
By Technology
  • Antibody Tests
    • HIV-1 Screening Tests
      • ELISA
      • Rapid Tests
      • Home Access Dried Blood Spot
    • HIV-1 Confirmatory Tests
      • Western Blot Tests
      • Indirect Immune Fluorescent Antibody Assays (IFA)
      • Line Immunoassays (LIA)
      • Radio-Immunoprecipitation Assays (RIPA)
    • HIV-2 & Group O Diagnostic Tests
  • Viral Load Tests
  • CD4 Tests
  • Tests for Early Infant Diagnosis
  • Tests for Viral Identification
By Application
  • Diagnostic laboratories
  • Hospitals
  • Blood Banks
  • Home care settings
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Abbott Laboratories, Merck & Co., Roche Diagnostics AG, Thermo-Fisher Scientific Inc., Danaher Corporation, Becton-Dickinson and Company, Bio-Rad Laboratories (U.S.), Hologic, Inc., Siemens-AG, Alere Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: HIV DIAGNOSIS MARKET, BY TECHNOLOGY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Technology

    • 4.2. Antibody Tests

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. HIV-1 Screening Tests

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. ELISA

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Rapid Tests

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Home Access Dried Blood Spot

          • 4.2.4.2.1. Market Size and Forecast

      • 4.2.4. HIV-1 Confirmatory Tests

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. Western Blot Tests

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Indirect Immune Fluorescent Antibody Assays (IFA)

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Line Immunoassays (LIA)

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Radio-Immunoprecipitation Assays (RIPA)

          • 4.2.4.2.1. Market Size and Forecast

      • 4.2.4. HIV-2 Group O Diagnostic Tests

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Viral Load Tests

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. CD4 Tests

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Tests For Early Infant Diagnosis

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Tests For Viral Identification

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: HIV DIAGNOSIS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Diagnostic Laboratories

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Hospitals

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Blood Banks

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Home Care Settings

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: HIV DIAGNOSIS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Technology

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Hiv Diagnosis Market

        • 6.2.5.1. Market Size and Forecast, By Technology
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Hiv Diagnosis Market

        • 6.2.6.1. Market Size and Forecast, By Technology
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Hiv Diagnosis Market

        • 6.2.7.1. Market Size and Forecast, By Technology
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Technology

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Hiv Diagnosis Market

        • 6.3.5.1. Market Size and Forecast, By Technology
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Hiv Diagnosis Market

        • 6.3.6.1. Market Size and Forecast, By Technology
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Hiv Diagnosis Market

        • 6.3.7.1. Market Size and Forecast, By Technology
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Hiv Diagnosis Market

        • 6.3.8.1. Market Size and Forecast, By Technology
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Hiv Diagnosis Market

        • 6.3.9.1. Market Size and Forecast, By Technology
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Hiv Diagnosis Market

        • 6.3.10.1. Market Size and Forecast, By Technology
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Hiv Diagnosis Market

        • 6.3.11.1. Market Size and Forecast, By Technology
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Technology

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Hiv Diagnosis Market

        • 6.4.5.1. Market Size and Forecast, By Technology
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Hiv Diagnosis Market

        • 6.4.6.1. Market Size and Forecast, By Technology
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Hiv Diagnosis Market

        • 6.4.7.1. Market Size and Forecast, By Technology
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Hiv Diagnosis Market

        • 6.4.8.1. Market Size and Forecast, By Technology
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Hiv Diagnosis Market

        • 6.4.9.1. Market Size and Forecast, By Technology
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Hiv Diagnosis Market

        • 6.4.10.1. Market Size and Forecast, By Technology
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Hiv Diagnosis Market

        • 6.4.11.1. Market Size and Forecast, By Technology
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Hiv Diagnosis Market

        • 6.4.12.1. Market Size and Forecast, By Technology
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Hiv Diagnosis Market

        • 6.4.13.1. Market Size and Forecast, By Technology
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Technology

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Hiv Diagnosis Market

        • 6.5.5.1. Market Size and Forecast, By Technology
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Hiv Diagnosis Market

        • 6.5.6.1. Market Size and Forecast, By Technology
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Hiv Diagnosis Market

        • 6.5.7.1. Market Size and Forecast, By Technology
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Hiv Diagnosis Market

        • 6.5.8.1. Market Size and Forecast, By Technology
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Hiv Diagnosis Market

        • 6.5.9.1. Market Size and Forecast, By Technology
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Hiv Diagnosis Market

        • 6.5.10.1. Market Size and Forecast, By Technology
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Siemens-AG

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Roche Diagnostics AG

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Abbott Laboratories

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Danaher Corporation

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Thermo-Fisher Scientific Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Merck And Co.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Becton-Dickinson And Company

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Hologic, Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Alere Inc.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Bio-Rad Laboratories (U.S.)

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HIV DIAGNOSIS MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL HIV DIAGNOSIS MARKET FOR ANTIBODY TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL HIV DIAGNOSIS MARKET FOR VIRAL LOAD TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL HIV DIAGNOSIS MARKET FOR CD4 TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL HIV DIAGNOSIS MARKET FOR TESTS FOR EARLY INFANT DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL HIV DIAGNOSIS MARKET FOR TESTS FOR VIRAL IDENTIFICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL HIV DIAGNOSIS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL HIV DIAGNOSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL HIV DIAGNOSIS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL HIV DIAGNOSIS MARKET FOR BLOOD BANKS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL HIV DIAGNOSIS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL HIV DIAGNOSIS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL HIV DIAGNOSIS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA HIV DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. U.S. HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. CANADA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 20. CANADA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. MEXICO HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE HIV DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 27. FRANCE HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. GERMANY HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 29. GERMANY HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. ITALY HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 31. ITALY HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 33. SPAIN HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. UK HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 35. UK HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. RUSSIA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 37. RUSSIA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. REST OF EUROPE HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 39. REST OF EUROPE HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC HIV DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 42. ASIA-PACIFIC HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. CHINA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 44. CHINA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. JAPAN HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 46. JAPAN HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. INDIA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 48. INDIA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. SOUTH KOREA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 50. SOUTH KOREA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. AUSTRALIA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 52. AUSTRALIA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. THAILAND HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 54. THAILAND HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. MALAYSIA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 56. MALAYSIA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. INDONESIA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 58. INDONESIA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA HIV DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 62. LAMEA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 63. LAMEA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. BRAZIL HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 65. BRAZIL HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH AFRICA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH AFRICA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. SAUDI ARABIA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 69. SAUDI ARABIA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. UAE HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 71. UAE HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. ARGENTINA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 73. ARGENTINA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. REST OF LAMEA HIV DIAGNOSIS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 75. REST OF LAMEA HIV DIAGNOSIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. SIEMENS-AG: KEY EXECUTIVES
  • TABLE 77. SIEMENS-AG: COMPANY SNAPSHOT
  • TABLE 78. SIEMENS-AG: OPERATING SEGMENTS
  • TABLE 79. SIEMENS-AG: PRODUCT PORTFOLIO
  • TABLE 80. SIEMENS-AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. ROCHE DIAGNOSTICS AG: KEY EXECUTIVES
  • TABLE 82. ROCHE DIAGNOSTICS AG: COMPANY SNAPSHOT
  • TABLE 83. ROCHE DIAGNOSTICS AG: OPERATING SEGMENTS
  • TABLE 84. ROCHE DIAGNOSTICS AG: PRODUCT PORTFOLIO
  • TABLE 85. ROCHE DIAGNOSTICS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 87. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 88. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 89. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 90. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 92. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 93. DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 94. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 95. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. THERMO-FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 97. THERMO-FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 98. THERMO-FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 99. THERMO-FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 100. THERMO-FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. MERCK AND CO.: KEY EXECUTIVES
  • TABLE 102. MERCK AND CO.: COMPANY SNAPSHOT
  • TABLE 103. MERCK AND CO.: OPERATING SEGMENTS
  • TABLE 104. MERCK AND CO.: PRODUCT PORTFOLIO
  • TABLE 105. MERCK AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. BECTON-DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 107. BECTON-DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 108. BECTON-DICKINSON AND COMPANY: OPERATING SEGMENTS
  • TABLE 109. BECTON-DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 110. BECTON-DICKINSON AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. HOLOGIC, INC.: KEY EXECUTIVES
  • TABLE 112. HOLOGIC, INC.: COMPANY SNAPSHOT
  • TABLE 113. HOLOGIC, INC.: OPERATING SEGMENTS
  • TABLE 114. HOLOGIC, INC.: PRODUCT PORTFOLIO
  • TABLE 115. HOLOGIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. ALERE INC.: KEY EXECUTIVES
  • TABLE 117. ALERE INC.: COMPANY SNAPSHOT
  • TABLE 118. ALERE INC.: OPERATING SEGMENTS
  • TABLE 119. ALERE INC.: PRODUCT PORTFOLIO
  • TABLE 120. ALERE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. BIO-RAD LABORATORIES (U.S.): KEY EXECUTIVES
  • TABLE 122. BIO-RAD LABORATORIES (U.S.): COMPANY SNAPSHOT
  • TABLE 123. BIO-RAD LABORATORIES (U.S.): OPERATING SEGMENTS
  • TABLE 124. BIO-RAD LABORATORIES (U.S.): PRODUCT PORTFOLIO
  • TABLE 125. BIO-RAD LABORATORIES (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV DIAGNOSIS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HIV DIAGNOSIS MARKET
  • FIGURE 3. SEGMENTATION HIV DIAGNOSIS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HIV DIAGNOSIS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHIV DIAGNOSIS MARKET
  • FIGURE 11. HIV DIAGNOSIS MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 12. HIV DIAGNOSIS MARKET FOR ANTIBODY TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. HIV DIAGNOSIS MARKET FOR VIRAL LOAD TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. HIV DIAGNOSIS MARKET FOR CD4 TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. HIV DIAGNOSIS MARKET FOR TESTS FOR EARLY INFANT DIAGNOSIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. HIV DIAGNOSIS MARKET FOR TESTS FOR VIRAL IDENTIFICATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. HIV DIAGNOSIS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 18. HIV DIAGNOSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. HIV DIAGNOSIS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. HIV DIAGNOSIS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. HIV DIAGNOSIS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. HIV DIAGNOSIS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: HIV DIAGNOSIS MARKET
  • FIGURE 29. Top player positioning, 2022
  • FIGURE 30. SIEMENS-AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. SIEMENS-AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. SIEMENS-AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. ROCHE DIAGNOSTICS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. ROCHE DIAGNOSTICS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. ROCHE DIAGNOSTICS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. DANAHER CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. THERMO-FISHER SCIENTIFIC INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. THERMO-FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. THERMO-FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. MERCK AND CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. MERCK AND CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. MERCK AND CO.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. BECTON-DICKINSON AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BECTON-DICKINSON AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. BECTON-DICKINSON AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. HOLOGIC, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. HOLOGIC, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. HOLOGIC, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. ALERE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. ALERE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. ALERE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. BIO-RAD LABORATORIES (U.S.): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. BIO-RAD LABORATORIES (U.S.): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. BIO-RAD LABORATORIES (U.S.): REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Hiv Diagnosis Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers